{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T10:22:15Z","timestamp":1778149335666,"version":"3.51.4"},"reference-count":51,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Urology"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Sodium glucose\u2010linked transport protein 2 inhibitors are relatively novel drugs, used for the treatment of type 2 diabetes mellitus. Their use since Pharmaceutical Benefits Scheme\u00a0approval in Australia has increased drastically, possibly due to the low risk of hypoglycemic events and their advertised cardiovascular mortality benefits. However, as with any novel drug, adverse effects regarding their use require medical practitioner awareness for optimal patient outcomes. This paper aims to cover the major urological implications, including those pertinent perioperatively, that concern this class of drugs. There is a clear risk of developing genital mycotic infections with the use of sodium glucose\u2010linked transport protein 2 inhibitors, including serious infections such as Fournier\u2019s gangrene. Evidence for developing urinary tract infections has been mixed. Sodium glucose\u2010linked transport protein 2 inhibitor\u2010induced lower urinary tract symptoms may have impacts on quality of life via pollakiuria and nocturia, of which there are increased reports. Perioperative use increases the risk of euglycemic diabetic ketoacidosis. It is recommended that sodium glucose\u2010linked transport protein 2 inhibitors be ceased perioperatively.<\/jats:p>","DOI":"10.1111\/iju.14624","type":"journal-article","created":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T09:01:35Z","timestamp":1624352495000},"page":"984-990","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Sodium glucose\u2010linked transport protein 2 inhibitors: An overview of genitourinary and perioperative implications"],"prefix":"10.1111","volume":"28","author":[{"given":"Mohit","family":"Chandrashekar","sequence":"first","affiliation":[{"name":"Faculty of Medicine The University of Queensland Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"Philip","sequence":"additional","affiliation":[{"name":"Department of Urology Mater Hospital Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Nesbitt","sequence":"additional","affiliation":[{"name":"Department of Urology Mater Hospital Brisbane Queensland Australia"},{"name":"School of Medicine Griffith University Gold Coast Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre","family":"Joshi","sequence":"additional","affiliation":[{"name":"Department of Urology Mater Hospital Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlon","family":"Perera","sequence":"additional","affiliation":[{"name":"Faculty of Medicine The University of Queensland Brisbane Queensland Australia"},{"name":"Department of Urology Mater Hospital Brisbane Queensland Australia"},{"name":"Department of Surgery Austin Health The University of Melbourne Melbourne Victoria"},{"name":"Department of Urology Western Health The University of Melbourne Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,6,22]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2018.1394152"},{"key":"e_1_2_7_3_1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MED.0000000000000311","article-title":"An update on sodium\u2010glucose co\u2010transporter\u20102 inhibitors for the treatment of diabetes mellitus","volume":"24","author":"Hsia DS","year":"2017","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-019-0903-4"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACO.0000000000000674"},{"key":"e_1_2_7_9_1","unstructured":"Australian Government Department of Health.Pharmaceutical Benefits Scheme\u00a0(PBS). [Cited 25 Oct 2019.] Available from URL:http:\/\/www.pbs.gov.au\/pbs\/home"},{"key":"e_1_2_7_10_1","unstructured":"Department of Human Services.Pharmaceutical benefits schedule item reports.2019. [Cited 16 Oct 2019.] Available from URL:http:\/\/medicarestatistics.humanservices.gov.au\/statistics\/pbs_item.jsp"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14065"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-017-1301-x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.2217\/whe-2016-0001"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0457-8"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13820"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2013.12.052"},{"key":"e_1_2_7_17_1","first-page":"1","article-title":"Physician experiences with sodium\u2010glucose cotransporter (SGLT2) inhibitors, a new class of medications in type 2 diabetes, and adverse effects","volume":"20","author":"Patakfalvi L","year":"2018","journal-title":"Prim. Health Care Res. Dev."},{"key":"e_1_2_7_18_1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/psb.1521","article-title":"SGLT2 inhibitors and risk of genitourinary infections","volume":"27","author":"Chaplin S","year":"2016","journal-title":"Prescriber"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijem.IJEM_159_17"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13531"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2013.04.012"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/0956462414533099"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2013.05.2650"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/myc.12292"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.2337\/db19-1224-P"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S105721"},{"issue":"1","key":"e_1_2_7_27_1","first-page":"A47","article-title":"4CPS\u2010013 Discontinuation of sodium\u2010glucose co\u2010transporter 2 inhibitors due to recurrent genitourinary infections","volume":"25","author":"Lorenzo MG","year":"2018","journal-title":"Eur. J. Hosp. Pharm."},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-001238"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.12896"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.7326\/M19-0085"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/3695101"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13508"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-022577"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01329-7"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.7326\/M18-3136"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2017-219335"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1413-8670(10)70078-7"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.111637"},{"key":"e_1_2_7_39_1","first-page":"e9069","article-title":"Gauging the risk factors for asymptomatic bacteriuria in type\u20102 diabetic women: a case\u2010control study","volume":"12","author":"Zaidi SMJ","year":"2020","journal-title":"Cureus"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2020.11.075"},{"key":"e_1_2_7_41_1","volume-title":"EAU Guidelines on Urological Infections 2018","author":"Bonkat G","year":"2018"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4663-6"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1104429"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12245-019-0240-0"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0885"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bja.2019.03.028"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/anae.14251"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12630-017-1018-6"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACO.0000000000000735"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000002377"},{"key":"e_1_2_7_51_1","unstructured":"TraillR.Severe euglycaemic ketoacidosis withSGLT2inhibitor use in the perioperative period.2018. [Cited 17 Oct 2019.] Available from URL:http:\/\/www.anzca.edu.au\/documents\/alert\u2010dka\u2010and\u2010oral\u2010hypoglycaemics\u201020180215.pdf"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2019.1602116"}],"container-title":["International Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.14624","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/iju.14624","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.14624","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,5]],"date-time":"2023-11-05T06:00:20Z","timestamp":1699164020000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/iju.14624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,22]]},"references-count":51,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1111\/iju.14624"],"URL":"https:\/\/doi.org\/10.1111\/iju.14624","archive":["Portico"],"relation":{},"ISSN":["0919-8172","1442-2042"],"issn-type":[{"value":"0919-8172","type":"print"},{"value":"1442-2042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,22]]},"assertion":[{"value":"2020-12-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}